about
A DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cellsRapid construction of a dendritic cell vaccine through physical perturbation and apoptotic malignant T cell loadingThe Role of Invariant Natural Killer T Cells in Dendritic Cell Licensing, Cross-Priming, and Memory CD8(+) T Cell GenerationA Short History of the B-Cell-Associated Surface Molecule CD40CD40 immunotherapy for pancreatic cancerMechanisms of action of therapeutic antibodies for cancerAntigen presentation and the regulation of CD4 memory generation to influenza.Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients.MHC multimerization, antigen expression and the induction of APC amnesia in the developing immune response.Ex vivo assays of dendritic cell activation and cytokine profiles as predictors of in vivo effects in an anti-human CD40 monoclonal antibody ChiLob 7/4 phase I trialShaping successful and unsuccessful CD8 T cell responses following infection.Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccineIn vivo induction of a high-avidity, high-frequency cytotoxic T-lymphocyte response is associated with antiviral protective immunityRole of CD28/CD80-86 and CD40/CD154 costimulatory interactions in host defense to primary herpes simplex virus infection.Immunotherapy of AML: future directionsDendritic cell activation and cytokine production induced by group B Neisseria meningitidis: interleukin-12 production depends on lipopolysaccharide expression in intact bacteria.CD40-activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non-Hodgkin's lymphomaEnhanced signaling through the IL-2 receptor in CD8+ T cells regulated by antigen recognition results in preferential proliferation and expansion of responding CD8+ T cells rather than promotion of cell deathA DNA vaccine coding for the Brucella outer membrane protein 31 confers protection against B. melitensis and B. ovis infection by eliciting a specific cytotoxic response.Dendritic cell biology and regulation of dendritic cell trafficking by chemokines.CD40 ligand (CD154) and tumour necrosis factor-related apoptosis inducing ligand (Apo-2L) in haematological malignancies.CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection.Concurrent interaction of DCs with CD4(+) and CD8(+) T cells improves secondary CTL expansion: It takes three to tango.Evidence for antibody-mediated enhancement of simian immunodeficiency virus (SIV) Gag antigen processing and cross presentation in SIV-infected rhesus macaquesThe efficacy of genetic vaccination is dependent upon the nature of the vector system and antigen.Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors.The role of dendritic cell subsets in selection between tolerance and immunity.Cognate CD4 T-cell licensing of dendritic cells heralds anti-cytomegalovirus CD8 T-cell immunity after human allogeneic umbilical cord blood transplantationSystemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver Damage.CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells.In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance.Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients.Tissue-specific differential antitumour effect of molecular forms of fractalkine in a mouse model of metastatic colon cancer.DNA fusion gene vaccines against cancer: from the laboratory to the clinic.Immature dendritic cells acquire CD8(+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli.Targeting cytotoxic T lymphocytes for cancer immunotherapy.Immunization route dictates cross-priming efficiency and impacts the optimal timing of adjuvant deliveryImmunoglobulin Fc fragment tagging allows strong activation of endogenous CD4 T cells to reshape the tumor milieu and enhance the antitumor effect of lentivector immunization.CD40 ligand induces RIP1-dependent, necroptosis-like cell death in low-grade serous but not serous borderline ovarian tumor cells.Antisense therapy for restenosis following percutaneous coronary intervention.
P2860
Q24291798-3BB64E4E-8D7F-4964-B2A2-0AF569AA8CC5Q24815134-71C6293B-2726-4940-B42D-101BE6803A62Q26797344-F10339DB-207D-4932-BA2E-C4CCD290DD03Q27007137-C3794A98-F406-4D43-B330-E22C491A46E1Q27012550-CB1AAFE2-5C37-445F-B5E3-838283C4ECD1Q28385366-75B79010-CC08-45DD-98BB-60E1202F1D11Q30389279-7E2D19F7-2191-4099-B81D-65D14AF0B52AQ30846001-7DB2BD09-8425-4C84-835F-AD32DC02F632Q33547800-31DB02E4-1383-41F1-A467-78B88D474DA1Q33557015-FE0B577B-2296-4276-AD58-D220335A378DQ33771963-90D8F80D-13DC-4122-8AAE-ECB3F1B1A1AEQ33797285-CFF4732E-F8DC-4222-B1A3-8AA69A9AF2BEQ33806244-1485CBFE-F983-4D86-AB84-ABB322B57C75Q33835246-97B01A9E-D09F-4A40-ACC8-C7AD4C9294ECQ33893052-31ABF8DE-E4EC-44FC-91CD-9B4D66241925Q34008246-43CA4CC2-4037-4B1A-A9E1-80FD91655882Q34014497-54200127-751C-4240-AD61-C7C110FD1A50Q34015840-0D51BFF3-9FF9-4CA2-9F1C-389020F00E3DQ34033400-D566BE14-B697-47D8-8520-02C004C8588BQ34129744-63C3E5FE-DFE9-4594-BBE0-E277DF92063AQ34266298-5D348841-04CE-4D3D-9853-17B6B4527AF0Q34339494-8F6D4E3C-0128-4A7A-A5D9-92FEF9F3A6F6Q34438014-1897CB84-E6F7-4EEC-9AAE-EE68B40A1E31Q34462167-A72D3038-7C57-43E1-A7C0-815DA476754DQ34482074-735CB9F9-5EE8-4F0E-8116-AACDBD9FD265Q34616576-CE8DAE19-A93E-4488-AD6A-3538C98D6B59Q34842295-2035632D-692E-493A-A155-9A0F932BC958Q34991001-7301BD4D-1D94-436D-A910-60D1CD373575Q35572171-6BAD3406-4122-4E2B-AA32-9B5C86FB7ED3Q35602700-1C76FA32-2014-41B3-858B-2319E19A2620Q35653114-D756C23C-0E38-4E79-AB14-D231A85337F1Q35748591-167D5DEF-0D1C-42E7-89D2-808F39F0E60EQ35761379-CB4EB274-9B48-43A6-993D-9FAE19947FECQ35826392-70C6C138-7714-4F41-ADA3-15ED825BBE57Q35834680-53A8A4E0-DB0D-4E9F-99A1-D96BD7C78E21Q35842135-97CC747E-9CB6-484D-8087-0B215C30BEF2Q35928216-5C6753BF-A3A0-4858-94E6-C24787F96505Q35982675-CDA1A7F0-176D-45F7-BCDF-F47C662A25E1Q36022324-695EFB20-CAF6-4DDA-AAAD-AC63CCCA7BD2Q36040825-FD1D65A1-7CAC-4696-842E-61DCFE0B4067
P2860
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Immunology. Licence to kill.
@en
Immunology. Licence to kill.
@nl
type
label
Immunology. Licence to kill.
@en
Immunology. Licence to kill.
@nl
prefLabel
Immunology. Licence to kill.
@en
Immunology. Licence to kill.
@nl
P2860
P356
P1433
P1476
Immunology. Licence to kill.
@en
P2093
A Lanzavecchia
P2860
P2888
P304
P356
10.1038/30845
P407
P577
1998-06-01T00:00:00Z
P6179
1013306901